Skip to main navigation Skip to search Skip to main content

Tra‐1‐60: A new serum marker in patients with germ‐cell tumors

  • J. Marrink
  • , P. W. Andrews
  • , P. J. Van Brummen
  • , H. J. De Jong
  • , D. T.H. Sleijfer
  • , H. Schraffordt Koops
  • , J. W. Oosterhuis

Research output: Contribution to journalArticlepeer-review

17 Citations (Scopus)

Abstract

TRA‐1‐60 is a monoclonal antibody (MAb) that recognizes a mucin‐like antigenic determinant expressed on the surface of embryonal carcinoma (EC) progenitor cells. In order to determine whether this antigen is released into the serum of patients with a non‐seminomatous germ‐cell tumor (NSGCT), we developed a sensitive 2‐step immunoenzymometric assay. Of 42 EC‐positive NSGCT patients tested, 32 (76%) were found to release TRA‐1‐60‐reactive antigen into their serum, in contrast to 1 positive finding in 10 EC‐negative NSGCT patients. The marker was found in 67% (10/15) of the EC‐positive patients who were negative for both AFP and HCG. Sera from seminoma patients did not contain elevated levels of the TRA‐1‐60 antigen. Therefore, we propose that the TRA‐1‐60 antigen is a useful additional serum marker for following the progress of NSGCT(EC+) patients.

Original languageEnglish
Pages (from-to)368-372
Number of pages5
JournalInternational journal of cancer
Volume49
Issue number3
DOIs
Publication statusPublished - 30 Sept 1991
Externally publishedYes

Fingerprint

Dive into the research topics of 'Tra‐1‐60: A new serum marker in patients with germ‐cell tumors'. Together they form a unique fingerprint.

Cite this